M
Mika Kamata-Sakurai
Researcher at Chugai Pharmaceutical Co.
Publications - 12
Citations - 660
Mika Kamata-Sakurai is an academic researcher from Chugai Pharmaceutical Co.. The author has contributed to research in topics: Antibody & Antigen. The author has an hindex of 5, co-authored 7 publications receiving 452 citations.
Papers
More filters
Journal ArticleDOI
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
Takehisa Kitazawa,Tomoyuki Igawa,Zenjiro Sampei,Atsushi Muto,Tetsuo Kojima,Tetsuhiro Soeda,Kazutaka Yoshihashi,Yukiko Okuyama-Nishida,Hiroyuki Saito,Hiroyuki Tsunoda,Tsukasa Suzuki,Hideki Adachi,Taro Miyazaki,Shinya Ishii,Mika Kamata-Sakurai,Iida Takeo,Aya Harada,Keiko Esaki,Miho Funaki,Chifumi Moriyama,Eriko Tanaka,Yasufumi Kikuchi,Tetsuya Wakabayashi,Manabu Wada,Masaaki Goto,Takeshi Toyoda,Atsunori Ueyama,Sachiyo Suzuki,Kenta Haraya,Tatsuhiko Tachibana,Yoshiki Kawabe,Midori Shima,Akira Yoshioka,Kunihiro Hattori +33 more
TL;DR: A humanized bispecific antibody to factor IXa (FIXa) and factor X (FX), termed hBS23, that places these two factors into spatially appropriate positions and mimics the cofactor function of FVIII, exerted coagulation activity in FV III-deficient plasma, even in the presence of inhibitors.
Journal ArticleDOI
An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors
Takahiro Ishiguro,Yuji Sano,Shun-ichiro Komatsu,Mika Kamata-Sakurai,Akihisa Kaneko,Yasuko Kinoshita,Hirotake Shiraiwa,Yumiko Azuma,Toshiaki Tsunenari,Yoko Kayukawa,Yukiko Sonobe,Natsuki Ono,Kiyoaki Sakata,Toshihiko Fujii,Yoko Miyazaki,Mizuho Noguchi,Mika Endo,Asako Harada,Werner Frings,Etsuko Fujii,Eitaro Nanba,Atsushi Narita,Akihisa Sakamoto,Tetsuya Wakabayashi,Hiroko Konishi,Hiroaki Segawa,Tomoyuki Igawa,Takashi Tsushima,Hironori Mutoh,Yukari Nishito,Mina Takahashi,Lorraine Stewart,Ehab Elgabry,Yoshiki Kawabe,Masaki Ishigai,Shuichi Chiba,Masahiro Aoki,Kunihiro Hattori,Jun-ichi Nezu +38 more
TL;DR: This work developed ERY974, a whole humanized immunoglobulin G–structured TRAB harboring a common light chain, which bispecifically binds to GPC3 and CD3 and induced a robust antitumor efficacy even against tumors with nonimmunogenic features, which are difficult to treat by inhibiting immune checkpoints such as PD-1 and CTLA-4.
Journal ArticleDOI
Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation.
Mika Kamata-Sakurai,Yoshinori Narita,Yuji Hori,Takayuki Nemoto,Ryo Uchikawa,Masaki Honda,Naoka Hironiwa,Kenji Taniguchi,Meiri Shida-Kawazoe,Shoichi Metsugi,Taro Miyazaki,Naoko A. Wada,Yuki Ohte,Shun Shimizu,Hirofumi Mikami,Tatsuhiko Tachibana,Natsuki Ono,Kenji Adachi,Tetsushi Sakiyama,Tomochika Matsushita,Shojiro Kadono,Shun-ichiro Komatsu,Akihisa Sakamoto,Sayuri Horikawa,Ayano Hirako,Koki Hamada,Naoi Sotaro,Nasa Savory,Yasuko Satoh,Motohiko Sato,Yuki Noguchi,Junko Shinozuka,Haruka Kuroi,Ami Ito,Tetsuya Wakabayashi,Kamimura Masaki,Fumihisa Isomura,Yasushi Tomii,Noriaki Sawada,Atsuhiko Kato,Otoya Ueda,Yoshito Nakanishi,Mika Endo,Kou-ichi Jishage,Yoshiki Kawabe,Takehisa Kitazawa,Tomoyuki Igawa +46 more
TL;DR: A novel anti-CD137 switch antibody is generated, STA551, which exerts agonistic activity only in the presence of exATP, which demonstrates potent and broad anti-tumor efficacy against all mouse and human tumors tested and a wide therapeutic window without systemic immune activation in mice.
Journal ArticleDOI
Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974.
Hirotake Shiraiwa,Atsushi Narita,Mika Kamata-Sakurai,Takahiro Ishiguro,Yuji Sano,Naoka Hironiwa,Takashi Tsushima,Hiroaki Segawa,Toshiaki Tsunenari,Yosuke Ikeda,Yoko Kayukawa,Mizuho Noguchi,Tetsuya Wakabayashi,Akihisa Sakamoto,Hiroko Konishi,Taichi Kuramochi,Mika Endo,Kunihiro Hattori,Jun-ichi Nezu,Tomoyuki Igawa +19 more
TL;DR: The outline, prospects, and limitations of the common light chain format, which includes one of Chugai's proprietary technologies, termed ART-Ig technology, are introduced and some tips for de-risking the antibody when engineering a T cell redirecting antibody are described.
Journal ArticleDOI
Exploitation of Elevated Extracellular ATP to Specifically Direct Antibody to Tumor Microenvironment.
Futa Mimoto,Kanako Tatsumi,Shun Shimizu,Shojiro Kadono,Kenta Haraya,Miho Nagayasu,Yuki Suzuki,Etsuko Fujii,Kamimura Masaki,Akira Hayasaka,Hiroki Kawauchi,Kazuhiro Ohara,Masayuki Matsushita,Takeshi Baba,Hiroaki Susumu,Sakashita Takuya,Terushige Muraoka,Kosuke Aso,Hitoshi Katada,Eriko Tanaka,Kenji Nakagawa,Masami Hasegawa,Miho Ayabe,Tessai Yamamoto,Tanba Shigero,Takahiro Ishiguro,Takayuki Kamikawa,Takeru Nambu,Tatsuya Kibayashi,Yumiko Azuma,Yasushi Tomii,Atsuhiko Kato,Kazuhisa Ozeki,Naoaki Murao,Mika Endo,Junichi Kikuta,Mika Kamata-Sakurai,Masaru Ishii,Kunihiro Hattori,Tomoyuki Igawa +39 more
TL;DR: In this paper, the extracellular adenosine triphosphate (ATP) concentration is highly elevated in the tumor microenvironment (TME) and remains tightly regulated in normal tissues.